PD-L1 test shows utility as non-invasive option
July 2017
SHARING OPTIONS:

SAN DIEGO—A team of scientists from Epic Sciences, Yale University, the University of Southern California and UC San Diego recently shared work that demonstrated that the presence of PD-L1 protein on circulating cells from patients newly diagnosed with lung cancer forecasts poor survival when they are treated with standard-of-care therapeutics not including PD-1 inhibitors. Epic Sciences’ novel PD-L1 blood test was used on 112 patients recently diagnosed with lung cancer, who were then followed for up to four years. The results showed that PD-L1 being expressed in blood samples was associated with worse overall survival.
 
“This study presents the largest examination to date towards demonstrating clinical utility of a non-invasive PD-L1 blood test for advanced lung cancer,” said Ryan Dittamore, vice president of translational research and clinical affairs, Epic Sciences, and co-author on the study. “We are rapidly accelerating our clinical development of the PD-L1 blood test and other immune-oncology liquid biopsy tests to meet this important medical need.”

Back
 
CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.